Another study showed that combination treatment of GLS inhibitors with ICIs significantly decreased tumor volume in an ICI-resistant-tumor mouse model, and the possible underlying mechanism may via enhancing CD8+ T cell activities and by decreasing ARG1-expressing myeloid cells [179]. This evidence concerns the gene ARG1 and neoplasm.